Literature DB >> 29684570

Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.

Ronald A Strauss1, Nesreen Jawhari2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29684570     DOI: 10.1016/j.anai.2018.04.016

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  5 in total

1.  Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma.

Authors:  Jared Silver; Michael Bogart; Elizabeth Packnett; Juan Wu; Donna McMorrow; Beth Hahn
Journal:  J Asthma Allergy       Date:  2020-12-16

Review 2.  Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.

Authors:  David Charles; Jemma Shanley; Sasha-Nicole Temple; Anna Rattu; Ekaterina Khaleva; Graham Roberts
Journal:  Clin Exp Allergy       Date:  2022-03-09       Impact factor: 5.401

3.  Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.

Authors:  Camille Taillé; Pascal Chanez; Gilles Devouassoux; Alain Didier; Christophe Pison; Gilles Garcia; Jeremy Charriot; Stéphane Bouée; Alina Gruber; Celine Pribil; Arnaud Bourdin; Marc Humbert
Journal:  Eur Respir J       Date:  2020-06-25       Impact factor: 16.671

4.  Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.

Authors:  Jean-Pierre Llanos; Hector Ortega; Michael Bogart; Elizabeth R Packnett; Janna Manjelievskaia; Christopher F Bell; Beth Hahn
Journal:  J Asthma Allergy       Date:  2020-01-29

5.  Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.

Authors:  Tim Harrison; Giorgio Walter Canonica; Geoffrey Chupp; Jason Lee; Florence Schleich; Tobias Welte; Antonio Valero; Kim Gemzoe; Aoife Maxwell; Sandra Joksaite; Shibing Yang; Peter Howarth; Melissa K Van Dyke
Journal:  Eur Respir J       Date:  2020-10-15       Impact factor: 16.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.